Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
City of Hope Medical Center
Pfizer
Astellas Pharma Inc
Peking University
Arcus Biosciences, Inc.
Pfizer
Amgen
AstraZeneca
University of Rochester
Boehringer Ingelheim
Dana-Farber Cancer Institute
Merck Sharp & Dohme LLC
University of Utah
Shanghai Zhongshan Hospital
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Xijing Hospital
Abramson Cancer Center at Penn Medicine
University of Southern California
Eli Lilly and Company
AbbVie
Trishula Therapeutics, Inc.
TCRCure Biopharma Ltd.
Jiangsu Hansoh Pharmaceutical Co., Ltd.
ImmunoGenesis
Pancreatic Cancer Action Network
Hummingbird Bioscience
Ono Pharmaceutical Co. Ltd
NYU Langone Health
Amgen
Dana-Farber Cancer Institute
UNC Lineberger Comprehensive Cancer Center
Ono Pharmaceutical Co. Ltd
BioNTech SE
Mayo Clinic
University of California, San Diego
Takara Bio Inc.
Astellas Pharma Inc
Laekna Limited
Emory University
Sun Yat-sen University
Taiho Pharmaceutical Co., Ltd.
Lisata Therapeutics, Inc.
AstraZeneca
University of Chicago
Servier
MedImmune LLC